
Matter No.: 11141-003002 Page 1 of 15
Applicant(s): Lars E. French et al.
METHODS AND COMPOSITIONS FOR TREATING DISEASES
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS


Fig. 1



Matter No.: 11141-003002

Applicant(s): Lars E. French et al.
METHODS AND COMPOSITIONS FOR TREATING DISEASES
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

Fig. 2




Matter No.: 11141-003002 Page 3 of 15
Applicant(s): Lars E. French et al.
METHODS AND COMPOSITIONS FOR TREATING DISEASES
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

Fig. 3




Matter No.: 11141-003002 Page 4 of 15
Applicant(s): Lars E. French et al.
METHODS AND COMPOSITIONS FOR TREATING DISEASES
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

Fig. 4




Matter No.: 11141-003002 Page 5 of 15
Applicant(s): Lars E. French et al.
METHODS AND COMPOSITIONS FOR TREATING DISEASES
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

Fig. 5



Matter No.: 11141-003002 Page 6 of 15
Applicant(s): Lars E. French et al.
METHODS AND COMPOSITIONS FOR TREATING DISEASES
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS


Fig.



Applicant(s): Lars E. French et al.

METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

Fig. **7** 



Applicant(s): Lars E. French et al.
METHODS AND COMPOSITIONS FOR TREATING DISEASES
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

Fig. 8






Fig. 9




Matter No.: 11141-003002 Page 10 of 15
Applicant(s): Lars E. French et al.
METHODS AND COMPOSITIONS FOR TREATING DISEASES
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

Fig. 10



Matter No.: 11141-003002 Page 11 of 15
Applicant(s): Lars E. French et al.
METHODS AND COMPOSITIONS FOR TREATING DISEASES
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

Fig. 11



Matter No.: 11141-003002 Page 12 of 15

Applicant(s): Lars E. French et al.

METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

Fig. 12 A.




Fig. 12B.

	WB	WB
IVIG	Comp	Fas-Comp
98J30AB12	Negative	Positive
99A18AB11	Negative	Positive
98K13AB12	Negative	Positive
2620M081A	Negative	Positive
99A13AB11	Negative	Positive
2453397F	Negative	Positive
24568981	Negative	Positive
2470797G	Negative	Positive
2454198F	Negative	Positive
2470597G	Negative	Positive
Sandoglobulin	Negative	Positive
Anti-Fas Apo1	Negative	Positive
Vehicle	Negative	Negative

Applicant(s): Lars E. French et al.
METHODS AND COMPOSITIONS FOR TREATING DISEASES
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

F19. 13A.





Fig. 13B.

	FasL ELISA Inhibit	ion		
IVIG .	% Max at 30 mg/	/ml	Categorie	es
98J30AB12		45		2
99A18AB11		49		2
98K13AB12		49	· ·	2
2620M081A		60	Best	
99A13AB11		44		2
2453397F		26	Worst	
24568981		36		3
2470797G		39		3
2454198F		45		2
2470597G		48		2
Sandoglobulin		35		3
Vehicle	100% binding			
	1 hr Preincubation	n		

Fig. 13C.



Matter No.: 11141-003002

Page 14 of 15

Applicant(s): Lars E. French et al.

METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

Fig 14A.






Fig 14B.

	FasL Killing Inhibition	FasL Killing Inhibition	
IVIG	Start mg/ml	Peak mg/ml	Categories
98J30AB12	0.5	4	2
99A18AB11	1	8	3
98K13AB12	1	. 8	3
2620M081A	2	8	4
99A13AB11	1	. 15	4
2453397F	1	4	2
24568981	1	4	2
2470797G	1	4	2
2454198F	0.25	8	Best
2470597G	0.25	8	Best
Sandoglobulin	15	30	Worst
Vehicle	Negative	Negative	
	No Preincubation	No Preincubation	]

Fig. 14c.





Matter No.: 11141-003002 Page 15 of 15
Applicant(s): Lars E. French et al.
METHODS AND COMPOSITIONS FOR TREATING DISEASES
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

